SSC, Safe Save Medical Cell Sciences & Technology CO. engaged in the development of cancer immunotherapy, ADCTA is the invention of more than 50 years effort put on in USA and Taiwan by W.K. Yang, M.D. Ph.D., who is well noted as the leading authority of Glioblastoma, GBM healing in Asia. Based on the distinguished capability of ADCAT Knowhow, lean manufacturing and total quality assurance SSC will fast expand ADCTA to numbers of solid cancers and regions globally via kicking off clinical trials, establishment of overseas subsidiaries, out licensing of turnkey and patent authorization etc.
In ear ly September 2018, the Mini stry of Health and Welfare of Taiwan i ssued the revi sed provi sions of the “Admini strative Measures for the Implementation or Use of Medical Devices for Specific Medical Technology Inspection and Inspection”. The application of open cell therapy technology includes autoimmune cell therapy and cancer patients and entities for standard treatment failure. Patients with advanced cancer . The Shifu Cell Program will
rapidly promote ADCTA to more drug-f ree or terminally fatal cancers, such as metastatic lung cancer , colorectal cancer , pancreatic cancer , prostate cancer , recur rent ovar ian cancer , and breast cancer . Wait. Shifu Cell has cooperated with many hospital s in Nor th, Central and South Taiwan, and has been able to formally serve Taiwan's medical technology and cancer patients in the near
future. It has always adhered to the wor ld's pioneer ing and therapeutic leader of Taiwan's immune cell therapy, and hopes to become a global standard for immune cell therapy through more successful cases of treating clinical patients.